Taiwan-based medical AI startup Neurobit Technology announced the completion of its Angel Round funding. Since its seed round, the company has raised more than NT$32 million, reaching a valuation exceeding NT$100 million.
Investors in this round include the National Development Fund’s Angel Investment Program, BE Health Ventures (a leading venture capital firm focused on medical innovation), and Taipei Medical University Biomedical Accelerator, along with several individual angel investors from the healthcare industry.
Neurobit stated that the new funds will be used to expand its R&D team, complete FDA and TFDA regulatory clearances, and accelerate its market expansion across the United States, Europe, and Taiwan.
A Medical-Grade AI Solution for Dizziness and Stroke Screening
In clinical practice, dizziness has long been difficult to diagnose due to the lack of quantitative and qualitative tools. Neurobit has focused for years on developing AI-assisted decision-making systems for high-risk neurological disorders.
Its flagship product, the NeuroSpeed System, is currently the world’s only medical-grade AI solution for emergency dizziness and in-hospital stroke screening, and has already undergone successful clinical validation.
CEO Travis Yang stated that the team comprises experts in biomedical engineering, information technology, neurology, intellectual property, and business management.
“The NeuroSpeed system is based on neurological examination principles and leverages advanced eye-movement imaging algorithms powered by AI,” said Yang.
Through collaboration with Taipei Medical University–Shuang Ho Hospital and other medical centers, the system has demonstrated over 90% specificity in distinguishing central nervous system disorders such as stroke from vestibular system diseases.
Lightweight, portable, and easy to operate, the NeuroSpeed system offers rapid automated analysis, helping physicians efficiently identify patients with potential neurological emergencies directly in the clinic.
The system has received strong positive feedback from clinicians worldwide and is regarded as a pioneering solution in using ocular movement to rapidly screen for stroke.
From Prototype to FDA Clearance
Neurobit has released two generations of the NeuroSpeed system:
-
First Generation: Provided data for physician reference without making diagnostic decisions (classified as Class I in the U.S.).
-
Second Generation: Builds upon previous data to enable AI-based diagnostic analysis, thus classified as a Class II medical device, requiring FDA approval for commercialization.
The company plans to submit regulatory documentation by August and, with investors’ support, begin establishing U.S. regional distributor partnerships to bring the product to market.
Expanding International Collaboration
Beyond Taiwan and the U.S., Neurobit is also expanding into Europe, having partnered with the Hague Medical Center in the Netherlands to secure national-level ZonMw grants.
Together, they will launch a large-scale clinical trial involving 12 Dutch hospitals.
Travis Yang explained that this partnership originated from Neurobit’s participation in a European healthtech accelerator program in 2019, which facilitated collaborations with European medical professionals.
COO Roger Chen noted that dizziness is a global healthcare issue, with an estimated market size of US$2 billion in the U.S. and US$1.2 billion in Europe.
In the U.S. alone, over 10 million outpatient visits are related to dizziness each year — highlighting a massive unmet market need.
Investor Perspective and Future Vision
Arthur Chen, Managing Partner at BE Health Ventures, commented:
“Beyond emergency rooms and outpatient clinics, we see NeuroSpeed’s potential in ambulances and remote medical sites, serving as a rapid screening tool before neuroimaging such as MRI. This could enable high-risk neurological patients to receive immediate and appropriate care, reducing treatment delays.”
With support from clinical collaborators, Neurobit has amassed substantial medical data, further improving the accuracy and reliability of its system and paving the way for standardization in neurological screening.
Following this funding round, Neurobit will continue expanding beyond emergency and dizziness specialties to explore new medical applications.
“Ophthalmology will be one of our next major focuses,” said Yang.
“We aim to develop AI-powered medical hardware and software tailored to clinical and market needs, establishing a new paradigm where hardware drives software innovation and value creation in telemedicine.”
